PROCEPT BioRobotics Corporation (PRCT)
NASDAQ: PRCT · Real-Time Price · USD
23.03
-1.06 (-4.40%)
At close: Apr 28, 2026, 4:00 PM EDT
23.64
+0.61 (2.65%)
After-hours: Apr 28, 2026, 7:54 PM EDT

Company Description

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.

It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.

The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.

PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

PROCEPT BioRobotics Corporation
PROCEPT BioRobotics logo
Country United States
Founded 2009
IPO Date Sep 15, 2021
Industry Medical Devices
Sector Healthcare
Employees 888
CEO Larry Wood

Contact Details

Address:
150 Baytech Drive
San Jose, California 95134
United States
Phone 650 232 7200
Website procept-biorobotics.com

Stock Details

Ticker Symbol PRCT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $25.00
CIK Code 0001588978
CUSIP Number 74276L105
ISIN Number US74276L1052
Employer ID 26-0199180
SIC Code 3841

Key Executives

Name Position
Larry L. Wood President, Chief Executive Officer and Director
Kevin Waters Executive Vice President and Chief Financial Officer
Alaleh Nouri EVice President, Chief Legal Officer and Corporate Secretary
Christofer Christoforou Executive Vice President of Operations
Barry Templin Executive Vice President and Chief Technology Officer
Matthew James Bacso C.F.A. Vice President of Investor Relations
Pooja Sharma Rao Executive Vice President and Chief Strategy and Marketing Officer
Stacey L. Porter Executive Vice President and Chief People Officer
Bijesh Chandran Executive Vice President of Regulatory Affairs and Quality Assurance
Stephen J. McGill Senior Vice President and GM of International

Latest SEC Filings

Date Type Title
Apr 22, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 22, 2026 DEF 14A Other definitive proxy statements
Mar 27, 2026 SCHEDULE 13G/A Filing
Mar 19, 2026 144 Filing
Mar 17, 2026 144 Filing
Mar 17, 2026 144 Filing
Mar 10, 2026 144 Filing
Mar 6, 2026 144 Filing
Mar 6, 2026 144 Filing
Mar 6, 2026 SCHEDULE 13G/A Filing